# EDGAR Filing Document

**Accession Number:** 0001798749
**File Stem:** 0000000000-26-004877
**Filing Date:** 2026-5
**Character Count:** 2370
**Document Hash:** 9a99031fada0af7c7e1d508c6312dd21
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-004877.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0000000000-26-004877

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260513

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jade Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001798749
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831377888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-295665

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** (781) 312-3013

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 23, SUITE 105
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerovate Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200103
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-212443

## Text-Extract

```

                                                            May 13, 2026

Elizabeth Balta, Esq.
Chief Legal Officer and Corporate Secretary
Jade Biosciences, Inc.
221 Crescent St., Building 23, Suite 105
Waltham, MA 02453

        Re: Jade Biosciences, Inc.
            Registration Statement on Form S-3
            Filed May 07, 2026
            File No. 333-295665
Dear Elizabeth Balta Esq.:
       This is to advise you that we have not reviewed and will not review your
registration
statement.
       Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    Matthew T. Bush, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._